Navigation Links
San Antonio Investigators Report on Mountain Cedar Allergy Model
Date:7/25/2013

San Antonio, TX (PRWEB) July 25, 2013

In the July 2013 issue of the Annals of Allergy, Asthma and Immunology, investigators in San Antonio, Texas describe the use of the mountain cedar season as a valuable tool for the assessment of new allergy medications and vaccines. The article, entitled "The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis," discusses the immune features of the pollen, reviews published studies and presents the daily pollen grain counts recorded over 18 years.

Dr. Charles Andrews, a Principal Investigator of the Biogenics Research Chamber and the lead author of the article notes that, “the mountain cedar pollen tsunami hits south-central Texas annually with a ferocity and dependability that have made the season a mainstay in allergy research.”

Thirty-eight studies from the scientific literature are presented, recognizing that many other studies, particularly generic drug trials, are unpublished. Analysis of the pollen counts provided by Dr. Paul Ratner reveals uniformity over many years that allows advance planning for successful natural season trials. Mountain cedar pollen has also been found to elicit major nasal and eye symptoms in multiple studies in the Biogenics Research Chamber. Utilizing mountain cedar pollen in the chamber model provides controlled trials for the evaluation of medications and vaccines, as well as allowing study of the basic inflammatory mechanisms of acute allergic reactions.

About the Company:

Biogenics Research Chamber located in San Antonio, Texas is the only large permanent pollen exposure testing facility in the United States. Dr. Robert Jacobs, Dr. Daniel Ramirez and Dr. Charles Andrews are the owners and Principal Investigators. The facility has a large chamber capable of testing up to 60 allergic participants at a time and a moderate sized chamber for testing up to 32 subjects. Both chambers utilize unique engineering and pollen delivery systems. Two additional chambers are being constructed. Compared to natural season allergy studies, the chambers offer controlled conditions without pollen concentration variation and weather interruptions. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials. In addition to commercial studies, the Biogenics Research Chamber has performed multiple academic trials examining the basic mechanisms of allergy.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10958220.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Texas Fertility Center Opens New Fertility Clinic in San Antonio
2. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
3. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
4. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
8. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
9. Global Printed and Flexible Sensors 2013 Report: Forecasts, Players, Opportunities
10. China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
11. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... There’s a ... for 2016 by the Orange County Register, after winning the award last year as ... a sought-after employer. President and COO Daniel Vesely pointed to the tech company’s upbeat ...
(Date:12/9/2016)... 9, 2016  A platform of orthopedic device technologies ... one step closer to becoming viable options for ... Inc., a start-up company from Philadelphia, ... for these novel absorbable bone fixation and regenerative ... commercial use. The company has leased space within ...
(Date:12/8/2016)... -- The Board of Directors of the Pittsburgh Life ... only pure life sciences investment firm, today announced ... plan developed by the Nominating and Governance Committee over ... F. Jordan is selected to serve as President ... , who is elected to the position of Executive ...
(Date:12/8/2016)... Philadelphia, PA (PRWEB) , ... December 08, 2016 ... ... fan engagement platforms, the business of innovation is taking over sports. On Thursday, ... executive will explore how technology is disrupting the playing field at a Smart ...
Breaking Biology Technology:
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/28/2016)... -- "The biometric system market projected ... biometric system market is in the growth stage and ... The biometric system market is expected to be valued ... of 16.79% between 2016 and 2022. Government initiative in ... smartphones, rising use of biometric technology in financial institutes ...
Breaking Biology News(10 mins):